Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of subcutaneous NNC0537-1482 in healthy individuals
NL-OMON59217Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of NNC0537-1482 in heart failure (HF), sponsored by Novo Nordisk. Started Oct 2024; status: completed.
02
Drugs
NNC0537-1482
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON59217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59217.